Discontinuation report THALOMID
| Report ID | 205531 |
| Drug Identification Number | 02355221 |
| Brand name | THALOMID |
| Common or Proper name | THALOMID |
| Company Name | BRISTOL-MYERS SQUIBB CANADA |
| Market Status | MARKETED |
| Active Ingredient(s) | THALIDOMIDE |
| Strength(s) | 200MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL ORAL |
| Packaging size | 2BLPx14 |
| ATC code | L04AX |
| ATC description | IMMUNOSUPPRESSANTS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2024-03-31 |
| Actual discontinuation date | 2024-03-31 |
| Remaining supply date | 2024-03-31 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 2344 BOUL. ALFRED-NOBEL, SUITE 300 ST-LAURENT, QUEBEC CANADA H4S 0A4 |
| Company contact information | For more information please contact the Customer Service Desk at 1-800-267-0005 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2024-04-01 | English | Compare |
| v4 | 2023-09-29 | French | Compare |
| v3 | 2023-09-29 | English | Compare |
| v2 | 2023-09-29 | French | Compare |
| v1 | 2023-09-29 | English | Compare |
Showing 1 to 5 of 5